Paquinimod

Drug Profile

Paquinimod

Alternative Names: 57-57; ABR-215757; SLE 57-57

Latest Information Update: 17 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Active Biotech
  • Class Amides; Quinolines; Skin disorder therapies; Small molecules
  • Mechanism of Action Calgranulin B modulators; T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Systemic scleroderma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Systemic scleroderma
  • Discontinued Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 16 Apr 2018 Paquinimod is available for licensing as of 16 Apr 2018. www.activebiotech.com
  • 11 Nov 2016 Suspended - Phase-II for Systemic scleroderma in Germany (PO) (Active Biotech pipeline, November 2016)
  • 11 Nov 2016 Suspended - Phase-II for Systemic scleroderma in Sweden (PO) (Active Biotech pipeline, November 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top